AIMS: This study was performed to describe clindamycin, administered either orally or intravenously, concentration-time courses to patients with osteomyelitis, to study the effects of different covariates on clindamycin pharmacokinetics and to simulate an optimized administration scheme. METHODS: Clindamycin concentrations were measured in 50 patients. A total of 122 plasma concentrations were available (58 from oral administration and 64 from i.v. infusion). A population pharmacokinetic model was developed with MONOLIX 4 software. RESULTS: A one compartment model adequately described the data. Clindamycin clearance increased significantly with body weight (BW). The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h(-1) (0.39), 70.2 l and 0.92 h(-1) , respectively. The bioavailability of the oral form was estimated to be 87.6%. According to BW, theoretical doses needed to reach a C(min) of 2 mg l(-1) were then calculated. CONCLUSIONS: The current recommendation of 600 mg three times daily seems to be effective up to 75 kg but the dose should be raised to 900 mg three times daily thereafter. These assumptions should be prospectively confirmed.
AIMS: This study was performed to describe clindamycin, administered either orally or intravenously, concentration-time courses to patients with osteomyelitis, to study the effects of different covariates on clindamycin pharmacokinetics and to simulate an optimized administration scheme. METHODS:Clindamycin concentrations were measured in 50 patients. A total of 122 plasma concentrations were available (58 from oral administration and 64 from i.v. infusion). A population pharmacokinetic model was developed with MONOLIX 4 software. RESULTS: A one compartment model adequately described the data. Clindamycin clearance increased significantly with body weight (BW). The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h(-1) (0.39), 70.2 l and 0.92 h(-1) , respectively. The bioavailability of the oral form was estimated to be 87.6%. According to BW, theoretical doses needed to reach a C(min) of 2 mg l(-1) were then calculated. CONCLUSIONS: The current recommendation of 600 mg three times daily seems to be effective up to 75 kg but the dose should be raised to 900 mg three times daily thereafter. These assumptions should be prospectively confirmed.
Authors: Y El Samad; E Havet; H Bentayeb; B Olory; B Canarelli; J-F Lardanchet; Y Douadi; F Rousseau; F-X Lescure; P Mertl; F Eb; J-L Schmit Journal: Med Mal Infect Date: 2008-08-20 Impact factor: 2.152
Authors: Michelle Gompelman; Nynke G L Jager; Eveline Wallenburg; Roger J M Brüggemann; Chantal P Bleeker-Rovers; Geert J A Wanten Journal: Eur J Drug Metab Pharmacokinet Date: 2021-09-07 Impact factor: 2.441
Authors: Y Yang; S Chen; F Yang; L Zhang; G Alterovitz; H Zhu; J Xuan; X Yang; H Luo; J Mu; L He; X Luo; Q Xing Journal: Pharmacogenomics J Date: 2016-08-16 Impact factor: 3.550
Authors: Michael J Smith; Daniel Gonzalez; Jennifer L Goldman; Ram Yogev; Janice E Sullivan; Michael D Reed; Ravinder Anand; Karen Martz; Katherine Berezny; Daniel K Benjamin; P Brian Smith; Michael Cohen-Wolkowiez; Kevin Watt Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.938
Authors: Daniel Gonzalez; Paula Delmore; Barry T Bloom; C Michael Cotten; Brenda B Poindexter; Elisabeth McGowan; Karen Shattuck; Kathleen K Bradford; P Brian Smith; Michael Cohen-Wolkowiez; Maurine Morris; Wanrong Yin; Daniel K Benjamin; Matthew M Laughon Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.938
Authors: Anil R Maharaj; Huali Wu; Christoph P Hornik; Antonio Arrieta; Laura James; Varsha Bhatt-Mehta; John Bradley; William J Muller; Amira Al-Uzri; Kevin J Downes; Michael Cohen-Wolkowiez Journal: J Pharmacokinet Pharmacodyn Date: 2020-04-22 Impact factor: 2.410
Authors: D Gonzalez; C Melloni; R Yogev; B B Poindexter; S R Mendley; P Delmore; J E Sullivan; J Autmizguine; A Lewandowski; B Harper; K M Watt; K C Lewis; E V Capparelli; D K Benjamin; M Cohen-Wolkowiez Journal: Clin Pharmacol Ther Date: 2014-06-20 Impact factor: 6.903